OVERALL breast cancer | ||||||||
---|---|---|---|---|---|---|---|---|
 | BMI <25 | BMI ≥25 | ||||||
Controls (n) | Cases (n) | OR* | 95% CI | Controls (n) | Cases (n) | OR | 95% CI | |
Duration of EPT (years) | ||||||||
 Never used | 6154 | 1056 | 1 | Reference | 6880 | 1402 | 1 | Reference |
  < =5 | 1740 | 316 | 1.20 | (1.00, 1.44) | 1812 | 420 | 1.13 | (0.97, 1.32) |
 >5 | 1623 | 495 | 1.96 | (1.64, 2.34) | 1615 | 456 | 1.31 | (1.12, 1.54) |
  p-trend* |  |  | <0.0001 |  |  |  | <0.0001 |  |
  p for interaction |  |  | 0.001 |  |  |  |  |  |
Luminal A-like breast cancer | ||||||||
 Duration of EPT (years) | ||||||||
  Never used | 3424 | 550 | 1 | Reference | 3892 | 789 | 1 | Reference |
   < =5 | 959 | 176 | 1.36 | (1.06, 1.74) | 987 | 243 | 1.22 | (0.99, 1.50) |
  >5 | 896 | 293 | 2.29 | (1.80, 2.91) | 906 | 270 | 1.38 | (1.12, 1.71) |
   p-trend |  |  | <0.0001 |  |  |  | 0.002 |  |
   p for interaction |  |  | 0.001 |  |  |  |  |  |
Luminal B-like HER2-negative breast cancer | ||||||||
 Duration of EPT (years) | ||||||||
  Never used | 850 | 173 | 1 | Reference | 887 | 178 | 1 | Reference |
   < =5 | 257 | 57 | 1.13 | (0.74, 1.71) | 295 | 59 | 0.83 | (0.54, 1.29) |
  >5 | 243 | 71 | 1.22 | (0.79, 1.88) | 256 | 47 | 0.83 | (0.51, 1.35) |
   p-trend |  |  | 0.34 |  |  |  | 0.37 |  |
   p for interaction |  |  | 0.03 |  |  |  |  |  |
Luminal B-like HER2-positive breast cancer | ||||||||
 Duration of EPT (years) | ||||||||
  Never used | 450 | 81 | 1 | Reference | 544 | 113 | 1 | Reference |
   < =5 | 137 | 16 | 0.85 | (0.40, 1.81) | 144 | 29 | 0.82 | (0.45, 1.49) |
  >5 | 127 | 28 | 1.56 | (0.67, 3.60) | 130 | 43 | 1.56 | (0.87, 2.78) |
   p-trend |  |  | 0.44 |  |  |  | 0.24 |  |
   p for interaction |  |  | 0.52 |  |  |  |  |  |
HER2-positive breast cancer | ||||||||
 Duration of EPT (years) | ||||||||
  Never used | 269 | 54 | 1 | Reference | 296 | 56 | 1 | Reference |
   < =5 | 80 | 16 | 1.14 | (0.44, 2.95) | 77 | 14 | 1.38 | (0.62, 3.08) |
  >5 | 49 | 13 | 1.53 | (0.57, 4.05) | 57 | 17 | 1.28 | (0.56, 2.93) |
   p-trend |  |  | 0.41 |  |  |  | 0.43 |  |
   p for interaction |  |  | 0.89 |  |  |  |  |  |
Triple-negative breast cancer | ||||||||
 Duration of EPT (years) | ||||||||
  Never used | 457 | 94 | 1 | Reference | 522 | 101 | 1 | Reference |
   < =5 | 123 | 20 | 0.96 | (0.45, 2.04) | 110 | 34 | 1.40 | (0.79, 2.47) |
  >5 | 113 | 25 | 1.27 | (0.56, 2.86) | 100 | 27 | 1.34 | (0.71, 2.54) |
   p-trend |  |  | 0.63 |  |  |  | 0.25 |  |
   p for interaction |  |  | 0.09 |  |  |  |  |  |